Evaluation of Chemotherapy in Bladder Cancer

The evaluation of prophylactic intravescial chemotherapy for superficial bladder cancer; treatment of TIS of the urinary bladder - first results of protocol of the EORTC protocol 30861; interferon alfa-AB 60 million vs 100 millions in intravesical prophylaxis of superficial bladder cancer; long-term follow-up of camptothecin instillation for prevention and treatment of urinary bladder tumors; the fate of G3 pTI bladder cancer - progression, recurrence and survival; whole layer needle biopsy to evaluate neoadjuvant therapy in invasive bladder cancer; laparoscopic lymphadenectomy - a new option for staging in bladder cancer; radical TUR and chemotherapy aiming at bladder preservation; BHCG and bladder cancer; the Cueto prospective study 84005 on neoadjuvant cisplatinum before radical cystectomy - survival at 3.5 years; progress report on the overview of two randomized trials of cisplatinum in invasive transitional cell carcinoma of the bladder; preliminary analysis of a random study of neoadjuvant chemotherapy plus cystectomy versus cystectomy in patients with invasive bladder carcinoma; EORTC studies on first-line chemotherapy in invasive bladder cancer; chemotherapy for advanced bladder cancer - three kinds of regimes (MVAC, CAP and CAF); role of chemo-Rx-therapy; neoadjuvant chemo and radiotherapy versus radiotherapy as precystectomy treatment in bladder cancer; is pelvis lymphadenectomy curative for N1 bladder tumors?; histological interpretation of the post chemotherapy urinary bladder cancer; chemotherapy in metastatic disease.